Denmark-based biotech Novo Nordisk (NYSE: NVO) is a longtime leader in the diabetes drug market. Some of the company's products in this area, such as Rybelsus and Ozempic, continue to be successful. However, one of Novo Nordisk's strengths beyond its solid lineup is its ability to innovate. The company's pipeline is full of exciting programs.

One in particular, icodec, looks destined to become a major growth driver for Novo Nordisk. Let's look at icodec's recent results from clinical trials and what they may mean for Novo Nordisk's future. 

Continue reading

Source Fool.com